2020 has been a year of uncertainty and confusion, from cancelled physician appointments to increased stress and concern to adoption of digital health tools in managing health. These remain uneasy times, and as we move closer toward a COVID-19 vaccine, uncertainty remains around its effectiveness. New survey results about the forthcoming vaccine show worry and hesitancy among patients and families, how it could impact complex medication therapies, and the motives behind its availability.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Paul V. Tyahla
Current on COVID-19: Remdesivir Approval, At-Home Test, Point of Care Materials, and NIH Partnership
Here is some of the latest news regarding the COVID-19 situation from the past week. Gilead’s Remdesivir Gets Emergency FDA Approval for COVID-19 Days after clinical data showed Gilead’s remdesivir was effective in shortening the recovery time of some patients hospitalized with COVID-19, the FDA has granted the drug emergency use authorization (EUA).
MicroMass Launches New Resource to Help People Adjust to New Normal Under COVID-19
During these trying times, everyone can use a little help to live a happier and healthier life. And to help you do that, MicroMass Communications has launched a new site: COVID Compass. Based on MicroMass’s experience in behavioral science and public health, the site offers resources to help people build skills to navigate this “new normal.” That includes scientifically proven techniques to support your wellness as well as take care of those who are close to you.
The Pivot: Can Healthcare Marketing Practices Evolve in the Wake of a Global Pandemic?
Most of the adages about change note that although it’s constant, necessary—and sometimes even welcome—evolution isn’t always easy. And as we’re witnessing amidst the response to the global coronavirus pandemic, unexpected change on a massive scale can be brutal. Yet even the most difficult transformations tend to leave some form of benefit in their wake.
The Digital Transformation of Empathy
As marketers, we’ve been taught for decades to sugarcoat and photoshop an ideal image, often masking the stark reality of what it means to be inflicted by a disease. Meanwhile, those who seek the help of modern medicine are left to sift through the mess of marketing messages when all they want are real answers. Digital is an opportunity to allow patients access to our industry in a more immediate, compelling, and honest way.
Demonstrating Value in the Real World
New therapies are hitting the market at an unprecedented pace, and the innovation behind the treatments combined with the proportion designed to treat rare diseases is putting pressure on every segment of the industry. Demonstrating the value of a new therapy’s benefits versus its price is the core of marketing new pharmaceuticals.
Expanded Access Programs Require Compassionate Communications to Keep Your Reputation Intact
No company wants to be seen as uncaring, least of all in the healthcare space. Clients I’ve supported in this sector are often passionate about their mission to bring new and better treatment options to patients. But companies’ intentions may be undermined or misconstrued if they fail to develop a communications plan for an expanded access or “compassionate use” program.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Paul V.
Contact Paul V., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack